Cooley Guides Cancer-Focused Biotech's $115M IPO Filing
Early-stage biotechnology firm Poseida Therapeutics Inc., which is developing therapies for multiple myeloma and prostate cancer, said in a late Friday filing with the U.S. Securities and Exchange Commission that it...To view the full article, register now.
Already a subscriber? Click here to view full article